Table 3

Adverse events prior to week 14

Adverse Event Outcome

Calcium acetate

(N = 46)

Placebo

(N = 64)

P-value


Patients with any adverse event

30 (65.2%)

42 (65.6%)

0.96


Any adverse event, rate (per subject per visit)

0.42

0.57

0.46


Patients with related adverse event

5 (10.9%)

9 (14.1%)

0.16


Related adverse event, rate (per subject per visit)

0.39

0.36

0.84


Adverse events related to medication by organ system class


Cardiac disorders

0

1 (1.6%)


Gastrointestinal disorders

3 (6.5%)

6 (9.4%)


General disorders

1 (2.2%)

0


Investigations

1 (2.2%)

0


Metabolism and nutrition disorders

2 (4.3%)

1 (1.6%)


Musculoskeletal and connective tissue disorders

0

1 (1.6%)


Skin and subcutaneous tissue disorders

0

1 (1.6%)


Vascular disorders

0

1 (1.6%)


Qunibi et al. BMC Nephrology 2011 12:9   doi:10.1186/1471-2369-12-9

Open Data